A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

7.6K views

DOI:

10.3791/57934

July 4th, 2018

In This Article

Summary

Here, we present a protocol to measure nasal potential difference in mice. The test quantifies the function of transmembrane ion transporters such as the cystic fibrosis transmembrane conductance regulator and the epithelial sodium channel. It is valuable to evaluate the efficacy of novel therapies for cystic fibrosis.

Abstract

The nasal potential difference test has been used for almost three decades to assist in the diagnosis of cystic fibrosis (CF). It has proven to be helpful in cases of attenuated, oligo- or mono-symptomatic forms of CF usually diagnosed later in life, and of CF-related disorders such as congenital bilateral absence of vas deferens, idiopathic chronic pancreatitis, allergic bronchopulmonary aspergillosis, and bronchiectasis. In both clinical and preclinical settings, the test has been used as a biomarker to quantify responses to targeted therapeutic strategies for CF. Adapting the test to a mouse is challenging and can entail an associated mortality. This paper describes the adequate depth of anesthesia required to maintain a nasal catheter in situ for continuous perfusion. It lists measures to avoid broncho-aspiration of solutions perfused in the nose. It also describes the animal care at the end of the test, including administration of a combination of antidotes of the anesthetic drugs, leading to rapidly reversing the anesthesia with full recovery of the animals. Representative data obtained from a CF and a wild-type mouse show that the test discriminates between CF and non-CF. Altogether, the protocol described here allows reliable measurements of the functional status of trans-epithelial chloride and sodium transporters in spontaneously breathing mice, as well as multiple tests in the same animal while reducing test-related mortality.

Introduction

For almost three decades, electrical potential difference (PD) measurements have been used to evaluate the functional status of transmembrane ion transporters expressed at the nasal mucosa, as representative of the distal airways1. As a multistep dynamic test2,3, nasal PD allows functional dissection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and epithelial sodium channel (ENaC) activity, both localized at the apical membranes of epithelial cells and exerting critical roles in airway surface hydration. The major clinical application of the nasal PD test is to assist i....

Access restricted. Please log in or start a trial to view this content.

Protocol

The studies and procedures were approved by the ethics committee for animal research of the UCL (2017/UCL/MD/015) and in agreement with the European Community regulations for animal use in research (CEE n° 86/609). The investigators are qualified for the animal experimentation following the Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes.

1. Pre-test Assessment and Management

  1. Prepare the double lumen nasal catheter.
    ​NOTE: A nasal catheter is made as a double lumen capillary tube, one lumen being used for the continuous perfusi....

Access restricted. Please log in or start a trial to view this content.

Results

In order to illustrate the characteristic ion transport abnormalities in CF, nasal PD measurements were performed following the protocol described above in an F508del-CF mouse and in a wild-type control of the FVB/129 genetic background from the Brussels colony of Cftrtm1Eur mice30. This clinically relevant model, harboring the most common and one of the most severe F508del-CFTR mutation23,24

Access restricted. Please log in or start a trial to view this content.

Discussion

The purpose of this paper is to describe an adequate protocol for measuring nasal PD under continuous perfusion of solutions in spontaneously breathing mice for a length of time required for testing the integrity of ion transporters, mainly CFTR and ENaC. All steps of the protocol have been carefully optimized to ensure full animal recovery and good quality and reproducible data. In particular, critical steps are anesthesia assessment and management, and adequate animal position and care during and after the test.

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

The authors thank Prof. J. Lebacq for critically editing the manuscript. Cftrtm1Eur (homozygous F508del-CFTR (FVB/129) mice were developed by the Erasmus MC, Rotterdam, The Netherlands, with the support of European Economic Community European Coordination Action for Research in Cystic Fibrosis EU FP6 LHHM-CT-2005-018932.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Portex polyethylene tube Smiths Medical, Hythe, Kent, England CT21 6JLPortex 800/100/500;2.0mm ID, 3.0 mmODto prepare capillary tubes for nasal probe
Electrode creamParker, Fairfield, NJ, USARedux creamto build electrode bridges
Ag/AgCl electrodesBiomedical, Clinton Township, MI, USAJNS BNT131-1,0measuring and reference electrodes
amiloride hydrochlorideSigma, St Louis, MI, USAA7410to prepare perfusion solutions
forskolinSigma, St Louis, MI, USAF6886to prepare perfusion solutions
Knick Portamess voltmeterElektronisch Meβgeräte, Berlin, GermanyPortavo 904 pHto measure potential difference
Paraly SW 112 Software Elektronisch Meβgeräte, Berlin, GermanyParaly SW112 softwareto capture potential difference data
midazolam Mylan, Hoeilaart, BelgiumDormicum 15mg/3mlto serve as anaesthetic premedication
fentanylJanssen Cilag, Berchem, BelgiumFentanyl-Janssen 0.05 mg/mlto serve as anaesthetic medication
medetomidineOrion Pharma, Espoo, FinlandDomitor 1 mg/mlto serve as anaesthetic medication
droperidol Janssen  Cilag, Berchem, BelgiumDehydrobenzperidol 2.5 mg/mlto serve as anaesthetic medication
clonidine Boehringer Ingelheim Pharma KG, Ingelheim am Rhein, GermanyCatapressan 0.15 mg/ml,to serve as anaesthetic medication
refernce IV catheterBecton Dickinson, Sandy, UT, USA24 GA x 0.75 IN, BD Insyte-Wto build electrode bridges
forceps Fine science Tools, Heidelberg, GermanyDumont #5, Fine science Toolsto place the nasal catheter
naloxone Braun Medical, Brussels, BelgiumNarcan, 0.4 mg/mlto serve as anaesthetic antagonist
atipamezole Zoetis, Bloomberg, BelgiumAntisedan, 5 mg/mlto serve as a medetomedine specific antidote 
Heating pads Harvard Apparatus, Holliston, MA, USA18,8x37,5 cm; 15,5x15,5 cmto avoid hypothermia during and after the test
Peristaltic pump P1GE Life Sciences, Uppsala, Sweden18111091to perfuse solutions in the mouse nose
cyanoacrylate glueLoctite, Henkel, Düsseldorf, Germany super glue 3to glue together two capillary tubes  for nasal probe
NaClSigma, St Louis, MI, USARES0926S-A7Pharma-Grade, USP
CaCl2.2H2OSigma, St Louis, MI, USAM7304Pharma-Grade, USP
MgCl2.6H2OSigma, St Louis, MI, USA1551128Pharma-Grade, USP
K2HPO4Sigma, St Louis, MI, USA1551139Pharma-Grade, USP
Na gluconateSigma, St Louis, MI, USAS2054Pharma-Grade, USP
Ca gluconateSigma, St Louis, MI, USAC8231Pharma-Grade, USP
MgSO4.7H2OSigma, St Louis, MI, USARES0089M-A7Pharma-Grade, USP
BD needle Becton Dickinson, Franklin Lakes, USABD 26G (0.45x10 mm)intraperitoneal injection

References

  1. Knowles, M., Gatzy, J., Boucher, R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. New England Journal of Medicine. 305 (25), 1489-1495 (1981).
  2. Middleton, P. G., Geddes, D. M., Alton, E. F. W.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Cystic Fibrosis Mouse ModelDouble Lumen Nasal CatheterPeristaltic Pump PerfusionAmiloride Response MeasurementChloride Free ResponseForskolin Response AnalysisAnesthesia Administration ProtocolAnimal Recovery Procedure